New Jersey A2120 requires NJ FamilyCare to reimburse inpatient providers for long-acting injectable antipsychotic drugs at the outpatient rate.
New Jersey A2120 mandates that NJ FamilyCare reimburse inpatient providers for long-acting injectable antipsychotic drugs at the outpatient reimbursement rate. This change ensures that the reimbursement rate for these drugs in an inpatient setting more accurately reflects the cost of the drug. Currently, NJ FamilyCare uses a Diagnosis Related Group (DRG) reimbursement system for inpatient services, which does not consider the high cost of these drugs.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.